跳至主要内容
临床试验/NCT05515731
NCT05515731已完成4 期

Platelet Rich Plasma as a Treatment For Resistant Corneal Ulcers

Alaa Gamal1 个研究点 分布在 1 个国家目标入组 14 人开始时间: 2021年1月1日最近更新:
适应症
干预措施

试验速览

阶段
4 期
状态
已完成
发起方
入组人数
14
试验地点
1
主要终点
Pain scale

研究概览

简要总结

This prospective study involved 14 patients aged > 18 years with RCUs not responding to conventional treatment. All patients were treated with E-PRP drops (one drop), preservative-free artificial tears, antibiotic eye drop four times daily and systemic vitamin A once daily for one month. All patients were examined at 1, 2, 4, 6 and 8 weeks after the treatment initiation. In each visit, the following parameters were assessed: best corrected visual acuity (BCVA), anterior segment, corneal healing, condition of the conjunctiva, presence of abnormal discharge and symptoms reported.

详细描述

The present prospective study involved 14 patients aged > 18 years with RCUs not responding to conventional treatment. All patients were treated with E-PRP drops (one drop), preservative-free artificial tears, antibiotic eye drop four times daily and systemic vitamin A once daily for one month. All patients were examined at 1, 2, 4, 6 and 8 weeks after the treatment initiation. In each visit, the following parameters were assessed: best corrected visual acuity (BCVA), anterior segment, corneal healing, condition of the conjunctiva, presence of abnormal discharge and symptoms reported.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
30 Years 至 50 Years(Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Resistant corneal ulcers

排除标准

  • •history of topical anesthetic abuse, diagnosed with corneal dystrophies, history of neurotrophic corneal ulcers or chemical burn ulcer. Other exclusion criteria were pregnancy of systemic diseases or therapies affecting platelets count e.g. aspirin.

研究组 & 干预措施

Autologous platelet-rich plasma eye drops

Experimental

Autologous platelet-rich plasma eye drops are derived from treatment of patients plasma using special process.

干预措施: Autologous platelet-rich plasma (PRP) eye drops (Biological)

结局指标

主要结局

Pain scale

时间窗: 8 weeks

Corneal pain as felt by the patient according to visual analog scale

次要结局

未报告次要终点

研究者

发起方
Alaa Gamal
申办方类型
Network
责任方
Sponsor Investigator
主要研究者

Alaa Gamal

Al-Azhar University

Egyptian Biomedical Research Network

研究点 (1)

Loading locations...

相似试验